Featured Research

from universities, journals, and other organizations

New details on molecular machinery of cancer

Date:
February 11, 2013
Source:
DOE/Lawrence Berkeley National Laboratory
Summary:
New details into the activation of a cell surface protein that has been strongly linked to a large number of cancers and is a major target of cancer therapies have been reported by Berkeley Lab researchers.

A structural coupling that allows intracellular kinase domains to undergo dimerization is a key to EGFR activation.
Credit: Image courtesy of DOE/Lawrence Berkeley National Laboratory

Researchers with Lawrence Berkeley National Laboratory (Berkeley Lab) and the University of California (UC) Berkeley have provided important new details into the activation of the epidermal growth factor receptor (EGFR), a cell surface protein that has been strongly linked to a large number of cancers and is a major target of cancer therapies.

"The more we understand about EGFR and the complex molecular machinery involved in the growth and proliferation of cells, the closer we will be to developing new and more effective ways to cure and treat the many different forms of cancer," says chemist Jay Groves, one of the leaders of this research. "Through a tour-de-force of quantitative biology techniques that included cutting edge time-resolved fluorescence spectroscopy in living cells, Nuclear Magnetic Resonance, and computational modeling, we've determined definitively how EGFR becomes activated through to its epidermal growth factor (EGF) ligand."

Groves, who holds joint appointments with Berkeley Lab's Physical Biosciences Division and UC Berkeley's Chemistry Department, and is also a Howard Hughes Medical Institute (HHMI) investigator is one of two corresponding authors of a paper in the journal Cell that describes this research. The paper is titled "Conformational Coupling across the Plasma Membrane in Activation of the EGF Receptor." The other corresponding author is John Kuriyan, who also holds joint appointments with Berkeley Lab, UC Berkeley and HHMI.

In high school biology classes we learn that genes contain coded instructions that are translated into the assembly of specific proteins. Many proteins, however, must be activated by post-translational processes such as autophosphorylation, the addition of phosphate. Protein activation can impact many important cellular processes including proliferation, differentiation and migration. Cancer is essentially a case of these cellular functions gone wild, often the result of problems with the EGFR. However, despite its well-established links to cancer, EGFR activation has only been partially understood.

"As a member of the large class of cell surface receptors known as receptor tyrosine kinases, EGFR features a ligand-binding domain on its extracellular side and a kinase domain on its intracellular side," Groves says. "The text-book explanation for EGFR activation is that the binding of EGFR's ligand, EGF, to its extracellular side induces dimerization of the receptor, which in turn brings together the kinase domains on the intracellular sides of the dimer, allowing them to phosphorylate one another."

Groves says while the picture is accurate, it is an oversimplification of the mechanics behind the process because isolated intracellular kinase domains in solution can be active on their own at relatively low concentration without EGF ligand-induced dimerization. Dimerization is the combining of two identical molecules into a single compound molecule.

Measuring autophosphorylation as a function of EGFR surface density in cells, Groves, Kuriyan and their colleagues found that structural coupling between the EGFR transmembrane helix and extracellular juxtamembrane modules in addition to EGF ligand-engagement is required for EGFR activation. This structural coupling permits dimerization to take place in the presence of the EGF ligand.

"The un-ligated EGFR sits in a structural configuration that prevents the intracellular kinase domains from being able to reach each other," Groves says. "When the EGF ligand binds, this restraint is removed, dimerization occurs, and one kinase phosphorylates the other."

The inclusion by Groves and his colleagues of time-resolved fluorescence spectroscopy on living cells is another new advance in bringing a quantitative approach to the biological sciences. By combining picosecond light pulses from two different colors of lasers into a single beam, then genetically modifying EGFRs to carry either a red or green fluorescent protein, the researchers were able to monitor in real time how EGFRs move and assemble into dimers during activation by the EGF ligands.

"Focusing on the cell membrane and monitoring each fluorescent photon emitted, then determining both its color and precise time of arrival at the detector, allows unambiguous assignment of which photon was triggered by which color light pulse," Groves says. "All of this can be done in real time and in living cells."

With the mechanics behind the activation of EGFR now fully explained, Groves and his colleagues are now applying their quantitative biology techniques to another group of receptor tyrosine kinases, the Eph receptors, as well as T cell receptors that are so important to the immune system.

"Our broader goal with these quantitative biology techniques is to transform biology into a hard physical science," Groves says. "The idea is to move from simply describing a collage of observations to being able to understand how biological systems work based on fundamental physics."

In addition to Groves and Kuriyan, other authors of this Cell paper were Nicholas Endres, Rahul Das, Adam Smith, Anton Arkhipov, Erika Kovacs, Yongjian Huang, Jeffrey Pelton, Yibing Shan, David Shaw and David Wemmer.

This research was primarily support by a grant from the National Cancer Institute.


Story Source:

The above story is based on materials provided by DOE/Lawrence Berkeley National Laboratory. Note: Materials may be edited for content and length.


Journal Reference:

  1. NicholasF. Endres, Rahul Das, AdamW. Smith, Anton Arkhipov, Erika Kovacs, Yongjian Huang, JeffreyG. Pelton, Yibing Shan, DavidE. Shaw, DavidE. Wemmer, JayT. Groves, John Kuriyan. Conformational Coupling across the Plasma Membrane in Activation of the EGF Receptor. Cell, 2013; 152 (3): 543 DOI: 10.1016/j.cell.2012.12.032

Cite This Page:

DOE/Lawrence Berkeley National Laboratory. "New details on molecular machinery of cancer." ScienceDaily. ScienceDaily, 11 February 2013. <www.sciencedaily.com/releases/2013/02/130211150753.htm>.
DOE/Lawrence Berkeley National Laboratory. (2013, February 11). New details on molecular machinery of cancer. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/2013/02/130211150753.htm
DOE/Lawrence Berkeley National Laboratory. "New details on molecular machinery of cancer." ScienceDaily. www.sciencedaily.com/releases/2013/02/130211150753.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Newsy (Sep. 30, 2014) The CDC says a new case of Ebola has not been reported in Nigeria for more than 21 days, leading to hopes the outbreak might be nearing its end. Video provided by Newsy
Powered by NewsLook.com
UN Ebola Mission Head: Immediate Action Is Crucial

UN Ebola Mission Head: Immediate Action Is Crucial

AFP (Sep. 30, 2014) The newly appointed head of the United Nations Mission for Ebola Emergency Response (UNMEER), Anthony Banbury, outlines operations to tackle the virus. Duration: 00:39 Video provided by AFP
Powered by NewsLook.com
CDC Confirms First Case of Ebola in US

CDC Confirms First Case of Ebola in US

AP (Sep. 30, 2014) The CDC has confirmed the first diagnosed case of Ebola in the United States. The patient is being treated at a Dallas hospital after traveling earlier this month from Liberia. (Sept. 30) Video provided by AP
Powered by NewsLook.com
New Breast Cancer Drug Extends Lives In Clinical Trial

New Breast Cancer Drug Extends Lives In Clinical Trial

Newsy (Sep. 30, 2014) In a clinical trial, breast cancer patients lived an average of 15 months longer when they received new drug Perjeta along with Herceptin. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins